Ray Patnaude – Page 7 – Safe Biologics

ASBM Letter to Congress: Paying Physicians to Prescribe Government-Preferred Biosimilars Undermines Patient-Physician Relationship

January 30, 2022

On December 2nd, ASBM sent a letter to House leaders reiterating our opposition to a proposal that would undermine the patient-physician relationship and distort the making of treatment decisions. The U.S. House of Representatives Committee on Rules has released new language for H.R. 5376 containing a provision that would pay physicians a 33% bonus for prescribing their […]

November 2021

January 5, 2022

OSU College of Pharmacy Launches ASBM-Developed CE Course on Biologics and Biosimilars The Ohio State University College of Pharmacy is now offering a 1-hour Continuing Education (CE) course entitled Biologics and Biosimilars: and Introduction. The course is presented by OSU professor and ASBM Advisory Board Chair Philip Schneider, FASHP, FFIP. The course is […]

OSU College of Pharmacy Releases Second ASBM-Authored Biosimilars Course

January 3, 2022

The Ohio State University College of Pharmacy is now offering a second 1-hour Continuing Education (CE) course presented by OSU professor and ASBM Advisory Board Chair Philip Schneider, FASHP, FFIP. The course is entitled “Biosimilar Substitution and Interchangeability”, and discusses how biosimilars are substituted at the pharmacy level in the U.S., and contrasts U.S. practices with […]

ASBM Featured in WHO Executive Summary of 73rd INN

December 12, 2021

The World Health Organization recently published the Executive Summary of its 73rd Consultation on International Nonproprietary Names, at which ASBM presented on October 19, 2021. From the Executive Summary: Objections to the use of distinct non-proprietary names for biosimilars quote that they may imply inferiority, that they may undermine confidence in their use and may hinder uptake. […]

ASBM Chairman Moderates Webinar at DDNC Policy Conference

December 8, 2021

On November 15th, ASBM Chairman Ralph McKibbin, MD moderated a panel discussion at the Digestive Disease National Coalition’s Fall policy-setting forum. The Fall Forum ran from November 15th-19th and gathered together policymakers, caregivers, and patients to discuss the latest developments in digestive disease policy. The webinar included an overview of DDNC funding priorities, presentations from DDNC member […]

ASBM Letter Opposes BIll That Would Undermine Physician-Patient Relationship

December 8, 2021

House Bill Would Distort Treatment Decisions, Undermine Physician-Patient Relationship On December 2nd, ASBM sent a letter to House leaders reiterating our opposition. The U.S. House of Representatives Committee on Rules has released new language for H.R. 5376 containing a provision that would pay physicians a 33% bonus for prescribing their patient the government-preferred biosimilar. The bill calls for […]

ASBM’s Madelaine Feldman Testifies at House Oversight Committee

December 2, 2021

On November 17th, ASBM’s Immediate Past Chair Madelaine Feldman, MD, FACR testified at a public hearing of the Congressional Oversight Committee. Entitled “Reviewing the Role of Pharmacy Benefit Managers in Pharmaceutical Markets”, the hearing examined the role of PBMs in contributing to higher drug prices. From Dr. Feldman’s testimony: The out-of-pocket costs for these miraculous RA medications […]

October 2021 Newsletter

November 8, 2021

House Bill Would Distort Treatment Decisions, Undermine Physician-Patient Relationship The U.S. House of Representatives Committee on Rules has released new language for H.R. 5376 containing a provision that would pay physicians a 33% bonus for prescribing their patient the government-preferred biosimilar. The bill calls for a “temporary increase in Medicare Part B payments for certain biosimilars,” […]

FDA Finalizes Guidance on Biosimilar Development

November 2, 2021

In October, the FDA finalized its guidance document “Questions and Answers on Biosimilar Development and the BPCI Act: Guidance for Industry”, addressing additional questions and answers related to biosimilar development. This is the second such revision to the guidance. The update added five questions, including: Sponsor responsibilities related to pediatric assessments for proposed biosimilar products The […]

ASBM Presents at WHO’s 73rd INN Consultation

October 25, 2021

On October 19th, ASBM participated in the World Health Organization’s 73rd Consultation on International Nonproprietary Names (INN) for Pharmaceutical Substances, held in Geneva, Switzerland. This was the seventeenth INN Consultation in which ASBM has participated. ASBM was represented by Executive Director Michael Reilly, Esq., and Advisory Board Chair Philip Schneider, MS, FASHP. While the discussions at the […]